Lyndra Therapeutics Achieves Critical Milestones Despite COVID-19 Headwinds

Lyndra Therapeutics Achieves Critical Milestones Despite COVID-19 Headwinds Örn Almarsson named Chief Technology Officer   Phase I trial for ultra-long-acting oral therapy for schizophrenia completes dosing  28% employee growth to date in 2020 to support manufacturing and pipeline expansion  WATERTOWN, Mass., June 10, 2020 – Lyndra Therapeutics, a clinical-stage biotech company working to make daily pills a
-> Continue reading Lyndra Therapeutics Achieves Critical Milestones Despite COVID-19 Headwinds